• 29.03.2019 – 09:41

  Micreos

  Micreos Raises EUR30 Million for Endolysin Technology Set to Replace Antibiotics / Funding for clinical development program XZ.700 and Gladskin Eczema USA launch

  THE HAGUE, Netherlands (ots) - Dutch biotechnology company Micreos announced it has secured EUR30 million in funding to accelerate the development of its endolysin technology, set to replace antibiotics. Proceeds are earmarked for the clinical development program of its endolysin XZ.700 and the USA launch of its ...

• 26.02.2019 – 09:00

  Debiopharm International SA

  Debiopharm International SA Initiates a Clinical Trial Phase II study evaluating afabicin in Bone and Joint Infections

  Lausanne, Switzerland (ots) - Debiopharm International SA (Debiopharm - www.debiopharm.com/debiopharm-international/), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate its antibiotic afabicin (Debio 1450) ( ...

• 21.02.2019 – 09:48

  Technische Universität München

  Salt could be a key factor in allergic immune reactions like atopic dermatitis

  TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22731 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/detail/article/35257/ Pictures: https://mediatum.ub.tum.de/1475815 NEWS RELEASE Salt could be a key factor in allergic immune reactions Atopic dermatitis: elevated ...

• 20.05.2011 – 16:37

  Astellas Pharma Europe Limited

  Astellas Receives Positive Opinion From CHMP for European Approval of VIBATIV(TM) for Nosocomial Pneumonia Caused by MRSA

  Staines, England (ots/PRNewswire) - Astellas Pharma Europe Ltd., announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of marketing authorisation for VIBATIV (telavancin hydrochloride) for the ...